Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Biosergen advances antifungal drug with strong Q1 results

Biosergen

Biosergen’s Q1 report highlights the successful completion of the second patient cohort in its BSG005 proof-of-concept clinical trial, targeting life-threatening fungal infections. CEO Tine Olesen describes the results as demonstrating real therapeutic potential, paving the way for the third cohort in Q4 2025. We reached out to Olesen for a comment.

Read the interview at biostock.se:

https://biostock.se/en/2025/05/biosergen-advances-antifungal-drug-with-strong-q1-results/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.